Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Histologically confirmed malignancy

  * Metastatic or unresectable disease
* Standard curative or palliative measures do not exist OR are no longer effective
* No CNS metastases
* No centrally-located non-small cell lung cancer

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Leukocytes ≥ 3,000/mm³
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST/ALT ≤ 2.5 times ULN (5 times ULN if known hepatic metastases)
* Urine protein to creatinine ratio ≤ 1.0 OR urine protein \< 1 g by 24 hour urine collection
* Creatinine clearance ≥ 50 mL/min OR creatinine normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during study and for up to 4 months after study treatment has stopped
* No uncontrolled hypertriglyceridemia (i.e., fasting serum triglyceride \> 350 mg/dL)
* No uncontrolled hypercholesterolemia (i.e., fasting serum cholesterol \> 300 mg/dL)
* No poorly controlled hypertension (i.e., blood pressure \> 160/100 mm Hg)
* No poorly controlled or clinically significant atherosclerotic vascular disease
* No thrombosis within 6 months
* No venous thromboembolic event within 6 months
* No arterial thromboembolic events within 12 months
* No cerebrovascular accident or transient ischemic attack in past 12 months
* No myocardial infarction or unstable angina in past 12 months
* No clinically significant peripheral vascular disease in past 12 months
* No New York Heart Association class II-IV congestive heart failure

  * Atrial or supraventricular tachycardias well controlled with beta blocker or calcium channel blocker allowed
  * Chronic pacemaker use allowed
* No serious cardiac arrhythmia requiring medication
* No other clinically significant cardiovascular disease
* No hemoptysis \> 1 tablespoon within 6 months
* No presence of bleeding diathesis
* No coagulopathy
* No presence of significant gastrointestinal (GI) disorders that would affect drug absorption
* No hemodynamically significant GI bleeding
* No history of intolerance to bevacizumab, everolimus, or erlotinib
* No other major bleeding event
* No ongoing or active infection
* No psychiatric illness or social situations that would limit safety or compliance with study requirements
* No other uncontrolled intercurrent illness

PRIOR CONCURRENT THERAPY:

* No angioplasty or cardiac or vascular stenting within the past 12 months
* No major surgery within past 28 days
* No other investigational agents within past 28 days
* No chemotherapy for cancer within past 21 days
* No biologic therapy for cancer within past 21 days
* No radiation therapy for cancer within past 21 days
* No hormonal therapy for cancer within past 21 days
* No minor surgical procedures within past 14 days
* No concurrent antiplatelet agents other than aspirin \< 325 mg/day
* No use of statin drugs other than pravastatin or atorvastatin
* Initiation of blood pressure (BP) medication is permitted prior to study entry provided that BP \< 150/90 mm Hg on 3 measurements over one week (study day -7 to 1) before starting treatment
* No concurrent grapefruit juice
* No concurrent therapeutic anticoagulation

  * Prophylactic low-dose anticoagulation for indwelling catheters is permitted
* No concurrent administration of any of the following drugs:

  * Nicardipine
  * Verapamil
  * Clotrimazole
  * Fluconazole
  * Itraconazole
  * Ketoconazole
  * Clarithromycin
  * Erythromycin
  * Troleandomycin
  * Cisapride
  * Metoclopramide
  * Bromocriptine
  * Cimetidine
  * Danazol
  * HIV-protease inhibitors (e.g., ritonavir, indinavir)
  * Hypericum perforatum (St. John's wort)
  * Carbamazepine
  * Phenobarbital
  * Phenytoin
  * Diltiazem
  * Rifabutin
  * Rifapentine
  * Rifampin